Recombinetics Announces New Chief Executive Officer

ST. PAUL, Minn.–(BUSINESS WIRE)–lt;a href=”” target=”_blank”gt;#crisprlt;/agt;–Recombinetics, a pioneer in gene-editing solutions for human health and
animal agriculture, today named Mark Platt the organization’s Chief
Executive Officer.

“Recombinetics is at the forefront of innovative research and
development to address issues of global significance, like feeding the
hungry, improving population health and the humane treatment of
animals,” Platt says. “I’m joining at this transformational time to
ensure the organization and its strategic investors thrive, with all
aligned to positively impact people, places and animals at home and

“Our organization will benefit greatly from Mark’s leadership
experience,” says Peter Hajas, chairman of the Board, Recombinetics.
“Mark brings an excitement for the possibilities of our innovative work
and is the right person to guide our corporate culture and nurture
relationships with key stakeholders to achieve goals of improving human
lives, feeding the world’s growing population, and reducing animal

Platt’s experience includes his time as President and CEO of Multistack,
LLC, in Sparta, Wis., where he provided strategic long-term direction of
the company and was directly involved in emerging technology, research
and development. From 2002 to 2012, Mark led the company through its
highest period of growth, with total revenue increasing by more than
1,000 percent.

Most recently Executive Sales Leader at the Trane, Inc. Midwest sales
office, Platt played a role in doubling the organization’s market share
in less than two years. He was also Senior Vice President of Business
Services for Gundersen Health System from November 2013 to April 2017.
In this role, Platt oversaw business development and marketing,
government relations, supply chain, facility operations and community
wellness initiatives. He has also served on the Gundersen Board of

Platt received his bachelor’s degree in electrical engineering from
Vanderbilt University, Nashville, Tenn. He was also a commissioned
officer in the U.S. Air Force with 17 years of service and held the rank
of captain in the U.S. Air Force Reserve.

Tammy Lee, who served as President and CEO of Recombinetics since August
2017, is taking a leave of absence from the company. Recombinetics
thanks Lee for her leadership, which included securing $34 million for
the company’s Series A financing round.

About Recombinetics
Founded in 2008, Recombinetics (RCI) has
a single gene-editing technology platform that supports three business
lines: Acceligen (precision breeding to enhance health, well-being and
productivity in food animals and aquaculture); Surrogen (gene-edited
swine models of human diseases for biomedical research and pre-clinical
trials by pharmaceutical and medical device companies); and Regenevida
(development of human regenerative products including cells, tissues and
organ products in swine models for exotransplantation to humans).

Recombinetics has a global intellectual property portfolio, with 22
patents issued and more than 300 patent filings on gene-editing methods,
traits, and novel reproduction methods in animals. Learn more at


Kris Huson, Recombinetics, Communications Manager

error: Content is protected !!